Cambridge Biologics, LLC is a leading provider of biological reagents in Life Science Research and Development, serving both academia and biopharmaceutical scientists. Our current products cover broad spectrum of biological areas such as Virology, Immunology, Oncology, and Neurology, with focuses on HIV-1/AIDS and influenza viruses, CD markers, T cell activation, Checkpoint Inhibitors, Cancer markers, Immuno-Oncology, Alzheimer and Parkinson disease. Using self-developed proprietary technologies, Cambridge Biologics has developed many lines of over 10,000 products, including polyclonal/monoclonal antibodies and recombinant proteins produced in mammalian cells (HEK 293 and CHO) and E.coli.

        In line with Cambridge Biologic’s business strategy, we are actively moving into the next phase of product developments. Our current product lines and technologies enable us to select preclinical candidates for R&D applications, such as suitable mAb for cancer markers, checkpoint inhibitors, T cell and NK cell activators, including humanization service and humanized drug candidates. With the rapid evolution in antibody drug development technologies, we also provide bispecific and multi-specific antibody drug platforms and R&D drug candidates.  Please contact us if you are interested in our products and services. Founded by scientists, and serving the scientists.